Measurements of body weight and height will be obtained. 05FPRF Immune Design Corp. IMDZ -04-1702 SAP Draft V1.0 for Protocol V2.0 Version Date: 2018- 05-25 Confidential 15 / 36 Table 2 Schedule of Events for the Treatment Period through Long -term Follow -up Period 05FPRF Immune Design Corp. IMDZ -04-1702 SAP Draft V1.0 for Protocol V2.0 Version Date: 2018- 05-25 Confidential 16 / 36 AE = adverse event; CT = computed tomography; ECOG = Eastern C ooperative Oncology Group; IHC = immunohistochemistry; MRI = magnetic resonance imaging; NY -ESO -1 = New York esophageal squamous cell carcinoma -1; QoL = quality of life; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event a Day 1 will occur within 28 days after the last dose of first- line systemic anti -cancer therapy or the last day of local regional therapy. Day 1 procedures must occur within 72 hours of randomization. b In the Boost Phase, tumor imaging will be performed e very 8 weeks for 1 year or until investigator -determined progressive disease, using RECIST v1.1, is documented. c The Post -treatment period will begin at the end of treatment and will continue until investigator -determined progressive disease, using RECIS T v1.1, is documented. If a subject has reached 12 months on study without disease progression, tumor imaging will be performed every 12 weeks ±7 days until disease progression. d The Long -term Follow -up period will begin at the time investigator -determin ed progressive disease (using RECIST v1.1) is documented and will continue for up to 5 years, until the date of death, or until sponsor notification of study closure. e The following information must be available at Day 1: subjects must have documented co mpletion of first- line systemic anti -cancer therapy and must have received at least 4 to 8 cycles of therapy (or no more than 180 days of systemic anti -cancer therapy); results of IHC testing for the presence of NY -ESO -1 (≥1% expression) must be available from the central laboratory; and the investigator -evaluated tumor response, using RECIST v1.1, to first -line systemic anti -cancer therapy must be documented. 05FPRF Immune Design Corp.